| Ocular Hypertension
Combigan vs Cosopt PF
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Combigan vs Cosopt Pf with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCosopt Pf has a higher rate of injection site reactions vs Combigan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cosopt Pf but not Combigan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Combigan
Cosopt Pf
At A Glance
Topical (ophthalmic)
Twice daily
Alpha-2 agonist / beta-blocker
Ophthalmic
Twice daily
Carbonic anhydrase inhibitor / beta-blocker
Indications
- Glaucoma
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Ocular Hypertension One drop in the affected eye(s) twice daily approximately 12 hours apart; if using multiple topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) twice daily; if other topical ophthalmic drugs are used, administer at least 5 minutes apart. Use the contents of each individual unit immediately after opening and discard any remaining solution.
Contraindications
- Bronchial asthma, history of bronchial asthma, or severe chronic obstructive pulmonary disease
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
- Neonates and infants (pediatric patients younger than 2 years old)
- Hypersensitivity to any component of this product
- Bronchial asthma or history of bronchial asthma, or severe chronic obstructive pulmonary disease
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
- Hypersensitivity to any component of this product
Adverse Reactions
Most common (5%-15%) allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, stinging
Serious hypersensitivity reactions, severe respiratory or cardiac reactions, cardiac failure, potentiation of vascular insufficiency, increased reactivity to allergens, potentiation of muscle weakness, masking of hypoglycemia, masking of thyrotoxicosis, ocular hypersensitivity
Postmarketing bradycardia, eyelid erythema, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (>=5%) Taste perversion (bitter, sour, or unusual taste), ocular burning and/or stinging (up to 30%), conjunctival hyperemia, blurred vision, superficial punctate keratitis, eye itching (5-15%)
Postmarketing Bradycardia, cardiac failure, cerebral vascular accident, chest pain, choroidal detachment following filtration surgery, depression, diarrhea, dry mouth, dyspnea, heart block, hypotension, iridocyclitis, myocardial infarction, nasal congestion, Stevens-Johnson syndrome, toxic epidermal necrolysis, paresthesia, photophobia, respiratory failure, skin rashes, urolithiasis, vomiting
Pharmacology
COMBIGAN combines brimonidine tartrate, a relatively selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow, with timolol maleate, a non-selective beta-1 and beta-2 adrenergic receptor inhibitor, to lower elevated intraocular pressure.
COSOPT PF combines dorzolamide hydrochloride (carbonic anhydrase II inhibitor) and timolol maleate (non-selective beta1/beta2-adrenergic receptor blocker); both components independently reduce elevated intraocular pressure by decreasing aqueous humor secretion, with additive IOP-lowering effect when combined.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Combigan
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Cosopt Pf
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Combigan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Cosopt Pf
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Combigan
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Cosopt Pf
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Combigan.
No savings programs available for Cosopt Pf.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CombiganView full Combigan profile
Cosopt PfView full Cosopt Pf profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.